NO159017B - Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater. - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater. Download PDFInfo
- Publication number
- NO159017B NO159017B NO813359A NO813359A NO159017B NO 159017 B NO159017 B NO 159017B NO 813359 A NO813359 A NO 813359A NO 813359 A NO813359 A NO 813359A NO 159017 B NO159017 B NO 159017B
- Authority
- NO
- Norway
- Prior art keywords
- tetrahydro
- carboxylic acid
- acid
- amino
- isoquinoline
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- 125000006239 protecting group Chemical group 0.000 claims abstract description 3
- -1 N-substituted amino Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 3
- 238000005897 peptide coupling reaction Methods 0.000 claims description 2
- BWKMGYQJPOAASG-UHFFFAOYSA-M 1,2,3,4-tetrahydroisoquinoline-3-carboxylate Chemical class C1=CC=C2CNC(C(=O)[O-])CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-M 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 2
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910001868 water Inorganic materials 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 10
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 10
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- JSDRRTOADPPCHY-UHFFFAOYSA-N 2-[2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)azaniumyl]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylate Chemical compound C1C2=CC=CC=C2CC(C(O)=O)N1C(=O)C(C)NC(C(=O)OCC)CCC1=CC=CC=C1 JSDRRTOADPPCHY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical class C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LDECUSDQMXVUMP-UHFFFAOYSA-N benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate Chemical compound O=C1NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)C(C(=O)OCC=2C=CC=CC=2)=C(C)N1CCCCCC(=O)N(CCCCCC)C(C(=O)NCCCC)C1=CC=C(OCC(=O)OC)C(C(=O)OC)=C1 LDECUSDQMXVUMP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLSLEGPOVLMJMN-UHFFFAOYSA-N 2-[2-[(1-carboxy-3-phenylpropyl)amino]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1C2=CC=CC=C2CC(C(O)=O)N1C(=O)C(C)NC(C(O)=O)CCC1=CC=CC=C1 FLSLEGPOVLMJMN-UHFFFAOYSA-N 0.000 description 1
- IBBLRJGOOANPTQ-UHFFFAOYSA-N 2-[2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1C2=CC=CC=C2CC(C(O)=O)N1C(=O)C(C)NC(C(=O)OCC)CCC1=CC=CC=C1 IBBLRJGOOANPTQ-UHFFFAOYSA-N 0.000 description 1
- IPWKRQDBMKJLFA-UHFFFAOYSA-N 2-[2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid hydrate hydrochloride Chemical compound O.Cl.C1C2=CC(OC)=C(OC)C=C2CC(C(O)=O)N1C(=O)C(C)NC(C(=O)OCC)CCC1=CC=CC=C1 IPWKRQDBMKJLFA-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-UHFFFAOYSA-N 2-[2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)azaniumyl]propanoyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylate Chemical compound C1C2=CC(OC)=C(OC)C=C2CC(C(O)=O)N1C(=O)C(C)NC(C(=O)OCC)CCC1=CC=CC=C1 UWWDHYUMIORJTA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BWYXEHBJIMGDEB-UHFFFAOYSA-N 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carboxylate Chemical compound C1NC(C(O)=O)CC2=C1C=C(OC)C(OC)=C2 BWYXEHBJIMGDEB-UHFFFAOYSA-N 0.000 description 1
- ROWPWZMWICGKBY-UHFFFAOYSA-N 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1NC(C(O)=O)CC2=C1C=C(OC)C(OC)=C2 ROWPWZMWICGKBY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001243 alanino group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HYKDEPCVBMNYCM-UHFFFAOYSA-N benzyl 1,2,3,4-tetrahydroisoquinolin-2-ium-3-carboxylate;chloride Chemical compound Cl.C1C2=CC=CC=C2CNC1C(=O)OCC1=CC=CC=C1 HYKDEPCVBMNYCM-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- ZLZXSWNRZFMSSS-UHFFFAOYSA-N ethyl 2-bromo-4-phenylbutanoate Chemical compound CCOC(=O)C(Br)CCC1=CC=CC=C1 ZLZXSWNRZFMSSS-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N gamma-phenylbutyric acid Natural products OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- NNKSEUBQDFHGAC-UHFFFAOYSA-N tert-butyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate;hydrochloride Chemical compound Cl.C1=CC=C2CNC(C(=O)OC(C)(C)C)CC2=C1 NNKSEUBQDFHGAC-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Hydrogenated Pyridines (AREA)
Description
Denne oppfinnelse angår fremstilling av substituerte acylderivater av 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-(S,S,S)-forbindelser med formelen
hvor
R er hydrogen, t-butyl eller benzyl;
er hydrogen eller lavere alkyl; ■
R2 er hydrogen, metyl eller etyl, og
X og Y er uavhengig av hverandre hydrogen, lavere alkyl,
lavere alkoksy eller hydroksy; og de farmasøytisk godtagbare salter derav.
Betegnelsene "lavere alkyl" og "lavere alkoksy" betyr en lineær eller forgrenet alkyl- eller alkoksygruppe med fra 1 til 4 karbonatomer.
Spesielt foretrekkes forbindelsene
2 - [2 - [ (l-karboksy-3-f eny lpropy 1) ami no ] - 1-oksopropyl!] -1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre; 2-[2 -[[1-(etoksykarbonyl)- 3-fenylpropy1]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre; 2 - [2- [ {1-kar bo ksy-3-f eny lpropy 1) ami no] - 1-oksopropyl,] -1,2,3,4-tetrahydro-6,7-dimetoksy-3 isokinolin-karboksylsyre;
2-[2-[[1-(etoksykarbonyl)-3-fenylpropy1]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolin-karboksylsyré;
og farmasøytisk godtagbare syreaddisjonssalter derav.
Forbindelsene med formel I har asymmetriske karbonatomer be-tegnet med stjerner. 1,2,3,4-tetrahydroisokinolin-3-karboksyl-syren som anvendes ifølge oppfinnelsen, har L (S) konfigurasjon. Denne konfigurasjon er vist å være nødvendig for å oppnå biologisk aktivitet, og de aktive forbindelser er således avledet fra enten (L(-) eller DL-1,2,3,4-tetrahydroisokinolin-3-karboksylsyre.
Optiske isomerer og diastereo-isomerer oppstår på grunn av chiralitet i de sentre som er merket med en stjerne i formel I, og forbindelsene som fremstilles ifølge oppfinnelsen, har S-konfigurasjonen i disse sentere.
Forbindelsene som fremstilles ifølge oppfinnelsen, kan eksistere i vannfri form såvel som i solvatisert form, inn-befattet hydratiserte former. Vanligvis er de hydratiserte former og de solvatiserte former med farmasøytisk godtagbare oppløsningsmidler likeverdige med den vannfrie eller ikke-solvatiserte form for denne oppfinnelses formål.
Forbindelsene med formel I fremstilles fra 1,2,3,4-tetra-hydroisokinolin-3-karboksylsyre ved først å beskytte karboksyl-syregruppen, fortrinnsvis som en ester, f.eks. med en lavere alkyl-, benzyl- eller trimetylsilylgruppe (Formel II):
hvor
X og Y er som ovenfor og R^ er en passende blokkert karboksylsyregruppe.
Ved å sammenknytte en 2-(4-fenylsmørsyre)-del med en glycin-eller L-alanin-del, som kan beskyttes som en ester, dannes et N-[2-(4-fenylsmørsyre)]-substituert glycin- eller L-alanin-derivat med formel III:
hvor
og R2 er som ovenfor.
Efter en eventuell selektiv avblokkering av syredelen på glycin- eller alanin-delen av produktet med formel III/ kan den resulterende monosyre kobles, via standard peptidkoblings-metoder til 1,2,3,4-tetrahydro-3-isokinolin-karboksylatet, beskyttet som en ester. Selektiv eller fullstendig fjernelse av estergruppene kan benyttes for å oppnå den ønskede forbindelse med formel I.
Forbindelsene oppnås typisk som en blanding av diastereoisomerer som kan separeres ved standard metoder for fraksjonert krystallisasjon eller kromatografi.
Forbindelsene som fremstilles ifølge oppfinnelsen, danner syresalter med forskjellige uorganiske og organiske syrer. De farmasøytisk godtagbare syreaddisjonssalter som fremstilles ifølge oppfinnelsen, kan fremstilles ved vanlige reaksjoner hvor først den frie aminosyre eller aminoester-formen av produktet omsettes med én eller flere ekvivalenter av den passende syre
for å oppnå det ønskede anion i et oppløsningsmiddel eller et medium hvor saltet er uoppløselig, eller i vann efterfulgt av fjernelse av vannet ved frysetørring. Saltene av sterke syrer foretrekkes. Farmasøytisk godtagbare syreaddisjonssalter er f.eks. saltene av saltsyre, bromhydrogensyre, svovelsyre, salpetersyre, eddiksyre, fumarsyre, eplesyre, maleinsyre og sitronsyre.
Virkningen av enzymet renin på angiotensinogen, et pseudoglobulin i blodplasma, fører til dekapeptidet angiotensin I. Angiotensin I omdannes ved hjelp av angiotensin-omdannende enzym (ACE) til oktapeptidet angiotensin II. Sistnevnte er en aktiv pressor-substans som man har antydet er det stoff som forårsaker forskjellige former for hypertensjon i forskjellige pattedyr, f.eks. rotter og hunder. Forbindelsene som fremstilles ifølge oppfinnelsen, griper inn i renin —> angiotensin I —> angiotensin II-forløpet ved å hemme angiotensin I-omdannende enzym og redusere eller eliminere dannelsen av pressor-substansen angiotensin II, og er derfor nyttige til å redusere eller lindre hypertensjon. Ved administrering av et preparat inneholdende én av eller en kombinasjon av forbindelser med formel I eller farmasøytisk godtagbare salter derav, lindres hypertensjon hos slike pattedyr som har denne lidelse. En enkelt dose, eller fortrinnsvis to til fire separate daglige doser, administrert i en mengde på ca. 0,1 til 100 mg pr. kg. pr. dag, fortrinnsvis ca. 1 til 50 mg pr. kg pr. dag, er passende for å redusere blodtrykket. Forbindelsen admini-streres fortrinnsvis oralt, men man kan også anvende parenteral administrering, så som subkutan, intramuskulær, intravenøs eller intraperitoneal.
In vitro ACE måling: Hemmende virkning på angiotensin-omdannende enzym (ACE) ble bestemt ved å måle marsvin-serum ACE i nærvær og fravær av prøveforbindelsen. ACE fra marsvin-serum og prøveforbindelsene ble forhåndsinkubert i 10 minutter før tilsetning av det merkede substrat <3>H-hippuryl-glycyl-glycin. Efter 60 minutters inkubering ved 37°C ble reaksjonen, stanset ved tilsetning av 0,IN HC1. ACE spalter hippuryl-glycyl-bindingen for å danne dipeptidet glycy1-glycin og 3 H-hippursyre. <3>H-hippursyren ble derefter ekstrahert med etylacetat og ACE for en gitt prøve ble beregnet som mengden av dannet ^n-hippursyre.
Forbindelsene som fremstilles ifølge oppfinnelsen, kan anvendes for å oppnå reduksjon av blodtrykk ved anvendelse i slike preparater som tabletter, kapsler eller eliksirer for oral administrering, eller i sterile oppløsninger eller suspensjoner for parenteral administrering. Ca. 10 til 500 mg av en forbindelse eller blanding av forbindelser med formel I eller II eller fysiologisk godtagbare salter derav blandes med en fysiologisk godtagbar bærer, hjelpestoff, bindemiddel, konserveringsmiddel, stabilisator, smaksstoff osv., i en egnet enhetsdoseform i henhold til vanlig farmasøytisk praksis. Mengden av aktivt stoff i disse preparater er slik at man opp-når en passende dosemengde i det angitte område.
Illustrerende eksempler på hjelpestoffer som kan anvendes
i tabletter, kapsler o.l., er de følgende: et bindemiddel så som tragakantgummi, akasiegummi, maisstivelse eller gelatin;
et hjelpestoff så som dikalsiumfosfat; et sprengmiddel så
som maisstivelse, potetstivelse, alginsyre o.l., et smøremiddel så som magnesiumstearat; et søtningsmiddel så som sukrose, laktose eller sakkarin; et smaksstoff så som peppermynte, vintergrøntolje eller kirsebær. Når enhetsdoseformen er en kapsel, kan den i tillegg til materialer av ovennevnte type inneholde et flytende bæremiddel så som en fet olje. Forskjellige andre materialer kan være til stede som belegg eller for på annen måte å modifisere enhetsdosens fysikalske form. For eksempel kan tabletter være belagt med skjellakk, sukker eller begge. En sirup eller eliksir kan inneholde den aktive bestanddel, sukrose som søtningsmiddel, metyl- og propyl-parabener som konserveringsmidler, ét farvestoff og et smaksstoff så som kirsebær- eller appelsin-smaksstoff.
Sterile preparater for injeksjon kan tilberedes i henhold til vanlig farmasøytisk praksis ved å oppløse eller suspendere den aktive forbindelse i et bæremiddel så som vann for injeksjon, en naturlig forekommende vegetabilsk olje så som sesam-olje, kokos-olje, jordnøttolje, bomullsfrøolje osv., eller et syntetisk, fett bæremiddel så som etyloleat eller lignende. Buffere, konserveringsmidler, antioksydasjonsmidler og lignende kan innføres i den grad det er nødvendig.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere. Eksempel 1-4 viser fjernelse av beskyt-telsesgruppen, Eksempel 5-7 viser omsetning av II + III, og eksempel 8 og eksempel 9-11 viser fremstilling av henholdsvis III og II.
Eksempel 1
2-[ 2-[[ 1-( etoksykarbonyl)- 3- fenylpropyl] amino]- 1- oksopropyl]-1, 2, 3, 4- tetrahydro- 6, 7- dimetoksy- 3- isokinolin- karboksylsyre-hydroklorid- hydrat ( S, S, S).
En mengde på 0,0079 mol av hydrokloridet av 2-[2-[Il-te toksykarbonyl) -3-f enylpropyl] amino]-1-oksopropyl]-1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolin-karboksylsyre-fenylmetylester (S,S,S) oppløst i 100 ml tetrahydrofuran ble katalytisk debenzylsrt med hydrogen og 0,5 g 20% Pd/kull ved lavt trykk. Katalysatoren ble' frafiltrert, og produktet ble utfelt som et forholdsvis ikke-hydroskopt, fast stoff ved tilsetning av en 10-dobbelt mengde eter; vekt 3,7 g (88%), sm.p. 120-140°C,
TLC (20% MeOH-CHCl3/Si02) én flekk, Rf 0,5-0,7;
[a]^<3>= + 31,6° (1,05% EtOH).
Analyse:
Beregnet for C27H34N2°7*HC1"H20: C 58'63' H 6'74' N'5,07 Funnet: C 58,59, H 6,38, N 5,06.
Det ikke-krystallinske diester-hydroklorid-utgangsmateriale som ble anvendt ovenfor, ble fremstilt ved behandling av 5,54 g (0,0079 mol) av maleatsaltet (fremstilt ved fremgangsmåten
ifølge eksempel 5) med et overskudd av mettet natriumbikarbonat, ekstraksjon av den frie base inn i 50% eter-etylacetat,
behandling av denne oppløsning med overskudd av hydrogenklorid og konsentrering ved redusert trykk.
Eksempel 2
2- [ 2- [ [ 1- ( etoksykarbonyl)- 3- fenylpropyl] amino]- 1- oksopropyl]-1, 2, 3, 4- tetrahydro- 3- isokinolinkarboksylsyre- hydroklorid-
hydrat ( S, S, S).
Fremgangsmåte A: Debenzylering.
2-[2-[[1-(etoksykarbonyl)-3-fenylpropyl]amino]-1-oksopropyl] -1,2,3,4-tetrahydro-3-isokinolinkarboksylsyre-fenylmetylester-maleat (S,S,S) (fremstilt ved fremgangsmåten ifølge eksempel 6) ble katalytisk debenzylert ved fremgangsmåten beskrevet i eksempel 1 for å gi produktet, sm.p. 105-120°C, utbytte 56%; TLC (20% Me0II-CHCl3/Si02) én flekk, Rf 0,5-0,6;
[a]p3= +10,9° (1,03% EtOH).
Analyse:
Beregnet for C^H^N^ • HC1-H20: C 60,90, H 6,75, N 5,68 Funnet: C 61,00, H 6,37, N 5,59.
Fremgangsmåte B: Via spaltning av 1,1-dimetyletylester.
En mengde på 100 g av tri fluoreddiksyre ble satt til 11,6 g (0,023 mol) 2-[2-[ [1-etoksykarbony1)-3-fenylpropyl]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-3-isokinolinkarboksylsyre-1,1-dimetyletylester (S,S,S) (fremstilt ved fremgangsmåten ifølge eksempel 7). Blandingen ble omrørt til oppløsning,
og 1 time ved romtemperatur. Mesteparten av trifluoreddiksyren ble fjernet på en rotasjonsinndamper, og gjenværende spor ble fjernet ved suksessiv tilsetning og fjerning på rotasjonsinndamper av 2 x 50 ml THF. Den gjenværende olje ble oppløst i ca. 400 ml tørr eter, og hydrokloridet ble utfelt ved tilsetning av en oppløsning av 1,0 g (overskudd) av tørt hydrogenklorid opp-løst i 20 ml tørr eter. Efter filtrering og vasking med tørr eter ble filterkaken oppløst i ca. 250 ml vann. Denne opp-løsning ble filtrert gjennom celite og frysetørret for å gi produktet som et partielt hydrat, 10,0 g (90%), sm.p. 113-120°C. Analyse: Beregnet for C25H3Q<N>2<0>5•<H>C1•3/4 H20: C 61,55, H 6,70, N 5,74 Funnet: C 61,51, H 6,49, N 5,70
Eksempel 3
2-[ 2-[( 1- karboksy- 3- fenylpropyl) amino]- 1- oksopropyl]- 1, 2, 3, 4-tetrahydro- 6, 7- dimetoksy- 3- isokinolinkarboksylsyre- hydroklorid-hydrat ( S, S, S).
"En oppløsning av 0,553 g (0,001 mol) 2-[2-[[ 1-(etoksy-karbonyl) -3-fenylpropyl]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolirikarboksylsyre-hydroklorid-hydrat (S,S,S)
(fremstilt ved fremgangsmåten ifølge eksempel 1) i 4 ml (0,004 mol) IN natriumhydroksyd og 4 ml metanol fikk stå ved romtemperatur i 20 timer. Reaksjonsblandingen ble satt til 5 ml IN saltsyre og konsentrert under redusert trykk. De siste mengder vann ble fjernet ved to påfølgende tilsetninger og fjerning under redusert trykk av 25 ml porsjoner av etanol. Den organiske del av residuet ble oppløst i 0,5 ml metanol. Kloroform (30 ml)
ble tilsatt, og oppløsningen ble tørret over natriumsulfat, behandlet med trekull, filtrert og konsentrert for å gi 0,45 g produkt. Dette amorfe materiale ble oppløst i 20 ml tetrahydrofuran, og 100 ml eter ble tilsatt for å felle ut et nesten hvitt, fast produkt, vekt 0,4 g, sm.p. 145-170°C, utbytte 80%,
TLC (20% Me0H-CHCl3/Si02), Rf 0,1 [a]^<3>= +37,8° (1,09% MeOH). Analyse: Beregnet for C25<H>30<N>2°7'<H>C1'H2°: C 57'19' H 6'34' N 5,34 Funnet: C 57,17, H 6,10, N 5,51
Eksempel 4
2-[ 2 - [ ( l- karboksy- 3- fenylpropy1) amino]- 1- oksopropyl]- 1, 2, 3, 4-tetrahydro- 3- isokinolinkarboksylsyre- hydroklorid- hemihydrat
( S, S, S)
2-[2-[[1-(etoksykarbonyl)-3-fenylpropyl]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre-hydroklorid-hydrat (S,S,S) ble behandlet ved fremgangsmåten beskrevet i eksempel 3 for å gi produktet, sm.p. 140-170°C, utbytte 39%, [a]^3= V+|4,5° (1,08% MeOH).
Analyse:
Beregnet for <C>2gN205•HC1•1/2 H20:
C 60,59, H 5,97, N 6,15, Cl 7,77 Funnet: C 60,58, H 6,04, N 5,89, Cl 7,04
Eksempel 5
2- [ 2- [ [ 1- ( etoksykarbonyl)- 3- fenylpropyl] amino]- 1- oksopropyl]-1, 2, 3, 4- tetrahydro- 6, 7- dimetoksy- 3- isokinolin- karboksylsyre-fenylmetylester- maleat ( S, S, S)
En omrørt oppløsning av 5,0 g -(0,0158 mol) etyl-a-[(l-karboksyetyl)amino]benzenbutanoat-hydroklorid (S,S) (fremstilt ved fremgangsmåten ifølge eksempel 8) i 200 ml metylenklorid ble behandlet suksessivt med 1,60 g (0,0158 mol) trietylamin,
2,14 g (0,0158 mol) 1-hydroksybenzotriazol, 5,16 g (0,0158 mol) 1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolin-karboksylsyre-fenylmetylester, fri base (S-form) (fremstilt ved fremgangsmåten ifølge eksempel 9), og derefter med 3,26 g (0,0158 mol) dicykloheksylkarbodiimid i 10 ml metylendiklorid. Dicykloheksyl-
urinstoff ble gradvis utskilt. Blandingen fikk stå ved romtemperatur natten over. Heksan (300 ml) ble tilsatt, og urinstoffet filtrert. Filtratet ble vasket med 250 ml mettet natriumbikarbonat, tørret over natriumsulfat og konsentrert for å fjerne oppløsningsmidde1. Det viskøse residuum ble utgnidd med 50 ml eter og filtrert for å fjerne uoppløselig stoff. Filtratet ble konsentrert for å gi 9,2 g (99%) urenset base.
Fremstilling av maleatsaltet: En oppløsning av 9,0 g (0,015 mol) av den urensede basen ovenfor i 50 ml etylacetat ble behandlet med en varm (40°C) oppløsning av 1,86 g (0,016 mol) maleinsyre i 50 ml etylacetat. Hvite krystaller ble utskilt, vekt 7,2 g (65%), sm.p. 139-141°C; TLC av basen (dannet
med vandig natriumbikarbonat-behandling av saltet og etylacetat-ekstraksjon) viste én flekk, Rf 0,7 (EtOAc/SiO.,) . Omkrystallisering fra etylacetat ga rent. materiale med samme smeltepunkt, [a]^<3> = +3,4° (1,05% EtOH).
Analyse:
Beregnet for C34<H>4Q<N>2<0>7•C4H404: C 64,74, H 6,29, N 3,98 Funnet: C 64,48, H 6,30, N 3,99.
Eksempel 6
2-[ 2-[[ 1-( etoksykarbonyl)- 3- fenylpr opyl] amino]- 1- oksopropyl]-1, 2, 3, 4- tetrahydro- 3- isokinolinkarboksylsyre- fenylmetylester-maleat ( S, S, S)
Etyl-a-[(1-karboksyetyl)amino]-benzenbutanoat-hydroklorid (S,S) (fremstilt ved fremgangsmåten ifølge eksempel 8) ble koblet med 1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre-feny1-metylester, fri base (S-form) (fremstilt ved fremgangsmåten ifølge eksempel 10) ved samme fremgangsmåte som ble anvendt i eksempel 5; utbytte, 61%; sm.p- 151-153°C (omkrystallisert fra etylacetat); TLC av basen viste én flekk, Rf 0,8 (EtOAc/Si02); [a]^<3> = -11,7° (1,0% MeOH).
Analyse:
Beregnet for <C>32<H>36<N>2°5'<C>4<H>4°4<:> C 67'°7' H 6'25' N 4'35 Funnet: C 66,58, H 6,09, N 4,25
Eksempel 7
2-[ 2-[[ 1- etoksykarbonyl)- 3- fenylpropyl] amino]- 1- oksopropyl]-1, 2, 3, 4- tetrahydro- 3- isokinolin- karboksylsyre- l, 1- dimetyletylester ( S, S, S)
En blanding av 8,38 g (0,03 mol) etyl-a-[(1-karboksyetyl)-amino]benzenbutanoat (fri aminosyre (S,S) (fremstilt ved fremgangsmåten ifølge eksempel 8), 8,09 g (0,03 mol) 1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre-l,1-dimetyletylester-hydroklorid (S-form) (fremstilt ved fremgangsmåten ifølge eksempel 11), 4,05 g (0,03 mol) 1-hydroksybenzotriazol og 250 ml THF ble avkjølt i et isbad til 3-5°C. Under omrøring ble 3,04 g (0,03 mol) trietylamin tilsatt, og derefter ble en oppløsning av 6,92 g (0,0335 mol) dicykloheksylkarbodiimid i 30 ml THF langsomt tilsatt dråpevis i løpet av 20 minutter. Reaksjonsblandingen ble omrørt ved 3-5°C i 1 time. Isbadet ble fjernet, og reaksjonsblandingen ble omrørt i ytterligere
3 timer. Den separerte blanding av trietylamin-hydroklorid og dicykloheksylurinstoff ble fjernet ved filtrering og vasket med THF. Filtratet ble inndampet ved rotasjonsinndampning for å fjerne alle flyktige stoffer. Den resulterende gummi ble oppløst i ca. 300 ml etylacetat. Efter filtrering gjennom celite ble etylacetatoppløsningen ekstrahert 2 ganger med 100 ml av en mettet natriumbikarbonatoppløsning, en gang med 7 5 ml av en 2N sitronsyreoppløsning, en gang med 100 mi av en mettet natriumbikarbonatoppløsning og en gang med 100 ml av en mettet natriumkloridoppløsning. Efter tørring med vannfritt MgSO^
og filtrering, ble etylacetat fjernet ved rotasjonsinndampning for å gi 16,9 g av en lysebrun gummi. Denne gummi ble oppløst i 350 ml kokende heksan og dekantert gjennom celite. Heksan-oppløsningen ble avkjølt i is, kimpodet og omrørt inntil krystallisering var godt igang. Produktet ble filtrert, vasket med kald heksan og tørret, vekt 11,6 g (78%), sm.p. 68,5-71°C, [a]^3= -12,2° (2% MeOH). Rent materiale hadde sm.p. 71-72°C, [a] 3= -12,6° (2% MeOH). Maleatsaltet hadde sm.p. 127,5-128,5°C, [a]^<3>= +46,4 (2% MeOH).
Eksempel 8
Etyl- a-[ ( 1- karboksyetyl) amino] benzenbutanoat- hydroklorid ( S, S)
En oppløsning av 2,0 g t-butylalanin (S-form) og 3,78 g etyl-2-brom-4-fenylbutanoat i 25 ml dimetylformamid ble behandlet med 1,8 ml trietylamin, og oppløsningen ble oppvarmet ved 70°C
i 18 timer. Oppløsningsmidlet ble fjernet under redusert trykk, og residuet ble blandet med vann og ekstrahert med etyleter.
Det organiske lag ble vasket med vann og tørret over magnesium-sulfat. Konsentrering av oppløsningen under redusert trykk ga den oljeaktige t-butylester av mellomproduktet som ved gass-væske-kromatografi ble funnet å være tilstrekkelig ren for videre anvendelse.
En oppløsning av 143,7 g av denne t-butylester i 630 ml .trifluoreddiksyre ble omrørt ved romtemperatur i 1 time. Opp-løsningsmidlet ble fjernet under redusert trykk, og residuet ble oppløst i etyleter og inndampet påny. Denne operasjon ble gjentatt. Derefter ble eteroppløsningen behandlet dråpevis med en oppløsning av hydrogenklorid-gass i etyleter inntil utfelling opphørte. Det faste stoffet, som ble oppsamlet ved filtrering, var en blanding av diastereoisomerer,
sm.p. 153-165°C, [a]^<3>= +3,6° (1% MeOH).
For å fraskille den foretrukne S,S-isomer ble en suspensjon av 10,0 g av blandingen i 200 ml metylenklorid omrørt ved romtemperatur i 5 minutter og filtrert, det faste stoff ble vasket med ytterligere metylenklorid og til slutt med eter. Det faste materialet, sm.p. 202-208°C (spaltn.), [a]^<3>= -29,3° (1% MeOH) var den mindre foretrukne diastereoisomer med R,S-konfigurasjon
(S angir delen avledet fra L-alanin). Den foretrukne S,S-diastereoisomer ble erholdt fra filtratet efter konsentrering og utgnidning av resiudet med eter, sm.p. 137-139°C, [alD = +31,3°
(1% MeOH).
Den frie aminosyre (S,S-form) ble fremstilt ved behandling av en vandig.oppløsning av hydrokloridet med mettet natrium-acetat. Produktet ble filtrert, vasket godt med kaldt vann og omkrystallisert fra etylacetat, sm.p. 149-151°C,
[a]^<3>= +29,7° (1% 0,1N HC1).
Eksempel 9
1, 2, 3, 4- tetrahydro- 6, 7- dimetoksy- S- isokinolin- karboksylsyre-fenylmetylester- hydroklorid ( S- form)
En blanding av 1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolinkarboksylsyre-hydroklorid (S-form) og 600 ml benzylalkohol ble mettet med hydrogenkloridgass. Temperaturen steg til 45°C. Blandingen ble omrørt ved romtemperatur i 3 dager. En relativt liten mengde av det faste stoffet ble frafiltrert> og filtratet ble behandlet med ca. 2 liter eter for å felle ut råproduktet, vekt 37,5 g, utbytte 83%. Rensning ble utført ved behandling med overskudd av mettet natriumbikarbonat, ekstraksjon av basen inn i etylacetat og utfelling av hydroklorid-saltet med HCl-gass. Omkrystallisering fra metanol-eter ga renset produkt, sm.p. 255-260°C, [a]p<3>= -81,3° (1,0% MeOH),
TLC (20% Me0H-CHCl3/Si02), én flekk Rf 0,8.
Analyse:
Beregnet for CigH21N04 • HC1: C 62 ,72 , H 6,10, N 3,85
Funnet: C 62,54, H 5,99, N 4,00.
Eksempel 10
1, 2, 3, 4- tetrahydro- 3- isokinolin- karboksylsyre- fenylmetylester-hydroklorid ( S- form)
Benzylalkohol, 750 ml, ble behandlet med 150 g kommersiell polyfosforsyre og oppvarmet og omrørt ved 90°C for å få en homogen blanding. Fast 1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre (S-form), 165,2 g, ble tilsatt. Blandingen ble omrørt i 4 timer ved 95-105°C og fikk derefter stå ved romtemperatur i 18 timer. En oppløsning av 18,5 g gassformig saltsyre i 2,5 1 vannfri eter ble tilsatt, og produktet ble langsomt utskilt ved avkjøling natten over. Filtrering ga det rå benzyl-1,2,3,4-tetrahydro-3-isokinolin-karboksylat-hydroklorid. Dette ble renset ved omkrystallisering to ganger fra etanol for å gi materialet med sm.p. 190,5-191°C,
[a]^<3>= -83,3° (1% 1:1 metanol/lN saltsyre).
Eksempel 11
1, 2, 3, 4- tetrahydro- 3- isokinolinkarboksylsyre- l, 1- dimetyletylester- hydroklorid ( S- form)
Denneforbindelsen ble fremstilt ved at 447 g isobutylen ble ført inn i en 0°C oppløsning av 63,5 g 1,2,3,4-tetrahydro-3-isokinolin-karboksylsyre (S-form) i 650 ml tørr dioksan og 65 ml konsentrert svovelsyre under nitrogen. Reaksjonskaret ble forseglet og rystet i 17 timer ved romtemperatur. Reaksjonskaret ble luftet, og reaksjonsblandingen ble hellet-over i 25 1 kald 2N natriumhydroksyd. Produktet ble ekstrahert inn i eter. Eteroppløsningen ble vasket med vann, tørret og konsentrert til ca. 500 ml. Denne oppløsning ble behandlet med overskudd av 6N isopropanolisk saltsyre for å felle ut produktet, som ble oppsamlet ved filtrering. En prøve som var renset ved omkrystallisering fra etanol/eter hadde sm.p. 190-192°C (spaltn.), [a]<p3> = -88,7° (2% MeOH).
Claims (3)
1. Analogifremgangsmåte for fremstilling av et terapeutisk aktivt substituert acylderivat av 1,2,3,4-tetrahydro-isokinolin-3-karboksylsyre (S,S,S) med formelen
hvor
R er hydrogen, t-butyl eller benzyl,
Ri er hydrogen eller lavere alkyl,
R2 er hydrogen, metyl eller etyl, og
X og Y er uavhengig av hverandre hydrogen, lavere alkyl, lavere alkoksy eller hydroksy,
hvor lavere alkyl og lavere alkoksy inneholder 1 til 4 lineære eller forgrenede karbonatomer;
og de farmasøytisk godtagbare salter derav, karakterisert ved peptidkobling av et passende substituert 1,2,3,4-tetrahydro-isokinolin-3-karboksylat med formelen
med en N-substituert aminosyre med formelen
hvor Rj_, R2, X og Y er som definert ovenfor, og R 3 er en passende blokkert karboksylsyregruppe, og eventuelt fjernelse av beskyttelsesgruppe(r), idet utgangsmaterialene eventuelt anvendes som salt, eller den fremstilte forbindelse omdannes til salt.
2. Fremgangsmåte som angitt i krav 1 for fremstilling av 2~[2~[[1-(etoksykarbonyl)-3-fenylpropyl]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-6,7-dimetoksy-3-isokinolinkarboksylsyre-hydroklorid-hydrat (S,S,S), karakterisert ved at det anvendes utgangsmaterialer hvor R2 er etyl, R^ er metyl, og X og Y er hver metoksy.
3. Fremgangsmåte som angitt i krav 1 for fremstilling av 2_[2-[[1-(etoksykarbonyl)-3-fenylpropyl]amino]-1-oksopropyl]-1,2,3,4-tetrahydro-3-isokinolinkarboksylsyre-hydroklorid-hydrat (S,S,S)', karakterisert ved at det anvendes utgangsmaterialer hvor R2 er etyl, er metyl og X og Y er hver hydrogen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19376780A | 1980-10-03 | 1980-10-03 | |
| US06/236,397 US4344949A (en) | 1980-10-03 | 1981-02-20 | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO813359L NO813359L (no) | 1982-04-05 |
| NO159017B true NO159017B (no) | 1988-08-15 |
| NO159017C NO159017C (no) | 1988-11-23 |
Family
ID=26889329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO813359A NO159017C (no) | 1980-10-03 | 1981-10-02 | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4344949A (no) |
| EP (2) | EP0096157B1 (no) |
| JP (1) | JPS5788164A (no) |
| KR (1) | KR880001326B1 (no) |
| AT (2) | ATE25974T1 (no) |
| AU (2) | AU551239B2 (no) |
| CA (3) | CA1341330C (no) |
| DD (1) | DD201787A5 (no) |
| DE (3) | DE3176029D1 (no) |
| DK (1) | DK163120C (no) |
| ES (1) | ES8301925A1 (no) |
| FI (2) | FI78690C (no) |
| GR (1) | GR75353B (no) |
| HK (1) | HK43389A (no) |
| IE (2) | IE52666B1 (no) |
| IL (1) | IL63806A (no) |
| LU (1) | LU88321I2 (no) |
| MX (1) | MX155144A (no) |
| MY (1) | MY100440A (no) |
| NL (2) | NL930077I2 (no) |
| NO (1) | NO159017C (no) |
| PH (1) | PH17740A (no) |
| SG (1) | SG15689G (no) |
Families Citing this family (169)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460775A (en) * | 1979-08-09 | 1984-07-17 | Norwich Eaton Pharmaceuticals, Inc. | 2-(3-Mercapto-1-oxopropyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives |
| US4595675A (en) * | 1979-09-19 | 1986-06-17 | Hoechst Aktiengesellschaft | Bicyclic α-iminocarboxylic acid compounds having hypotensive activity |
| US4616030A (en) * | 1979-12-07 | 1986-10-07 | Adir | Perhydroindole-2-carboxylic acids as antihypertensives |
| US4508729A (en) * | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
| US4644008A (en) * | 1979-12-07 | 1987-02-17 | Adir | Perhydroindole-2-carboxylic acids as antihypertensives |
| US4616031A (en) * | 1979-12-07 | 1986-10-07 | Adir | Perhydroindole-2-carboxylic acids as antihypertensives |
| US4616029A (en) * | 1979-12-07 | 1986-10-07 | Adir | Perhydromdole-2-carboxylic acids as antihypertensives |
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| US4565819A (en) * | 1979-12-07 | 1986-01-21 | Adir | Substituted imino diacids, their preparation and pharmaceutical compositions which contain them |
| EP0278530A3 (de) * | 1980-08-30 | 1989-08-02 | Hoechst Aktiengesellschaft | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung |
| ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| US4532342A (en) * | 1981-02-20 | 1985-07-30 | Warner-Lambert Company | N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| IN156096B (no) * | 1981-03-19 | 1985-05-11 | Usv Pharma Corp | |
| EP0065301A1 (en) * | 1981-05-18 | 1982-11-24 | Merck & Co. Inc. | Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same |
| DE3134933A1 (de) * | 1981-09-03 | 1983-03-31 | Hoechst Ag, 6230 Frankfurt | "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung" |
| DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| EP0081094A1 (en) * | 1981-11-12 | 1983-06-15 | Merck & Co. Inc. | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents |
| IE55867B1 (en) * | 1981-12-29 | 1991-02-14 | Hoechst Ag | New derivatives of bicyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation |
| IE54551B1 (en) * | 1982-01-22 | 1989-11-22 | Ici Plc | Amide derivatives |
| US4665087A (en) * | 1982-02-22 | 1987-05-12 | Ciba-Geigy Corporation | 1-(carbamyl, thiocarbamyl, and iminocarbamyl)-indoline derivatives |
| US4483850A (en) * | 1982-05-10 | 1984-11-20 | Merck & Co., Inc. | N-Terminal substituted oligopeptide converting enzyme inhibitors |
| US4617291A (en) * | 1982-05-14 | 1986-10-14 | Mead Johnson & Company | Angiotensin-converting enzyme inhibiting dipeptide derivatives |
| US4427665A (en) | 1982-05-19 | 1984-01-24 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions |
| EP0099709A3 (en) * | 1982-07-19 | 1985-11-13 | Imperial Chemical Industries Plc | Amide derivatives |
| US4500713A (en) * | 1982-09-23 | 1985-02-19 | Usv Pharmaceutical Corporation | Therapeutic dipeptides |
| DE3302125A1 (de) * | 1983-01-22 | 1984-07-26 | Boehringer Ingelheim KG, 6507 Ingelheim | Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung |
| US4659711A (en) * | 1983-01-31 | 1987-04-21 | Usv Pharmaceutical Corporation | 1,2,3,4-Tetrahydrophthalazine and hexahydropyridazine compounds for treating hypertension |
| DE3303344A1 (de) | 1983-02-02 | 1984-08-02 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern |
| GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3333455A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung n-alkylierter dipeptide und deren estern |
| DE3333454A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
| US4542234A (en) * | 1983-10-06 | 1985-09-17 | Usv Pharmaceutical Corp. | Process for the separation of (S,S) diastereoisomers |
| DE3345355A1 (de) * | 1983-12-15 | 1985-06-27 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester |
| DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
| US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
| US4584299A (en) * | 1984-05-21 | 1986-04-22 | Warner-Lambert Company | Method of treating heart failure and medicaments therefor |
| GB8422165D0 (en) * | 1984-09-01 | 1984-10-03 | Wellcome Found | Compounds |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4785089A (en) * | 1985-06-13 | 1988-11-15 | Ciba-Geigy Corporation | Novel sulfonic acid esters and their preparation |
| US4652668A (en) * | 1985-07-03 | 1987-03-24 | Biomeasure, Inc. | Aromatic amino acid derivatives |
| DE3529960A1 (de) * | 1985-08-22 | 1987-03-05 | Boehringer Ingelheim Kg | Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung |
| US5231084A (en) * | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
| EP0254032A3 (en) | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| EP0566157A1 (en) | 1986-06-20 | 1993-10-20 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4830853A (en) * | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
| US4793998A (en) * | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
| JP2535001B2 (ja) * | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| US5262436A (en) * | 1987-03-27 | 1993-11-16 | Schering Corporation | Acylamino acid antihypertensives in the treatment of congestive heart failure |
| US4761479A (en) * | 1987-03-30 | 1988-08-02 | Warner-Lambert Company | Crystalline quinapril and a process for producing the same |
| FR2620699B1 (fr) * | 1987-09-17 | 1990-06-01 | Adir | Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides |
| FR2620700B1 (fr) * | 1987-09-17 | 1990-06-01 | Adir | Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides |
| DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
| US5055588A (en) * | 1988-07-06 | 1991-10-08 | Daicel Chemical Industries Ltd. | Process for preparing N-substituted amino acid esters |
| US4912221A (en) * | 1988-10-27 | 1990-03-27 | Occidental Chemical Corporation | Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof |
| DD284030A5 (de) | 1988-11-24 | 1990-10-31 | Hoechst Ag,De | Verfahren zur herstellung von peptiden mit bradykinin-antagonistischer wirkung |
| ZA902661B (en) * | 1989-04-10 | 1991-01-30 | Schering Corp | Mercapto-acyl amino acids |
| JPH075530B2 (ja) * | 1989-11-21 | 1995-01-25 | シェリング・コーポレーション | カルボキシアルキルカルボニルアミノ酸エンドペプチダーゼ阻害剤 |
| AU7168091A (en) * | 1989-12-22 | 1991-07-24 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
| US5075302A (en) * | 1990-03-09 | 1991-12-24 | Schering Corporation | Mercaptoacyl aminolactam endopeptidase inhibitors |
| US6300361B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag | Stabilized pharmaceutical compositions comprising acid donors |
| US5173506A (en) * | 1990-08-16 | 1992-12-22 | Schering Corporation | N-(mercaptoalkyl)ureas and carbamates |
| TW197945B (no) * | 1990-11-27 | 1993-01-11 | Hoechst Ag | |
| TW258739B (no) * | 1992-04-04 | 1995-10-01 | Hoechst Ag | |
| US5977160A (en) * | 1992-04-10 | 1999-11-02 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| GB2266529A (en) * | 1992-05-01 | 1993-11-03 | Merck Sharp & Dohme | Tetrahydroisoquinoline derivatives |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5514801A (en) * | 1992-12-29 | 1996-05-07 | Monsanto Company | Cyclic sulfone containing retroviral protease inhibitors |
| PT739898E (pt) * | 1995-03-13 | 2002-03-28 | Aventis Pharma Gmbh | Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao |
| DE59706273D1 (de) | 1996-03-20 | 2002-03-21 | Hoechst Ag | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| FR2746394B1 (fr) | 1996-03-20 | 1998-05-29 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation, et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| DE19612067A1 (de) * | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
| ES2122941B1 (es) * | 1997-05-29 | 1999-07-01 | Esteve Quimica Sa | Procedimiento para la obtencion de quinapril clorhidrato y solvatos utiles para el aislamiento y purificacion de quinapril clorhidrato. |
| DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CN1144598C (zh) * | 1998-06-05 | 2004-04-07 | 沃尼尔·朗伯公司 | 利用氧化镁稳定的含ace抑制剂的组合物 |
| WO2000002862A1 (en) * | 1998-07-08 | 2000-01-20 | G.D. Searle & Co. | Retroviral protease inhibitors |
| US6191144B1 (en) | 1998-08-17 | 2001-02-20 | Warner-Lambert Company | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis |
| NZ333206A (en) | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
| US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
| CA2372387A1 (en) * | 1999-04-30 | 2000-11-09 | Natalie A. Dales | Ace-2 inhibiting compounds and methods of use thereof |
| US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
| CA2398995C (en) * | 2000-02-04 | 2014-09-23 | Children's Hospital Research Foundation | Lipid hydrolysis therapy for atherosclerosis and related diseases |
| CA2303481A1 (en) * | 2000-04-05 | 2001-10-05 | Bernard Charles Sherman | Pharmaceutical compositions comprising moexipril magnesium |
| FR2807430B1 (fr) * | 2000-04-11 | 2002-05-17 | Adir | Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril |
| JP4636780B2 (ja) | 2000-12-14 | 2011-02-23 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | 真性糖尿病の検出および予防のための炎症性マーカー |
| WO2003013434A2 (en) * | 2001-08-06 | 2003-02-20 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| US6984645B2 (en) * | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US20030157165A1 (en) * | 2002-02-01 | 2003-08-21 | Sherman Bernard Charles | Stable saccharide-free tablets comprising a salt of quinapril or moexipril |
| US20030215526A1 (en) * | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
| US7670769B2 (en) | 2002-05-09 | 2010-03-02 | The Brigham And Women's Hospital, Inc. | IL1RL-1 as a cardiovascular disease marker and therapeutic target |
| CA2388475C (en) | 2002-05-31 | 2009-12-08 | Brantford Chemicals Inc. | Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives |
| CN1681495B (zh) | 2002-08-19 | 2010-05-12 | 辉瑞产品公司 | 用于治疗过度增生性疾病的组合物 |
| US20050101640A1 (en) * | 2002-10-16 | 2005-05-12 | Recordati Ireland Limited | Lisinopril/lercanidipine combination therapy |
| US20040147566A1 (en) * | 2002-10-16 | 2004-07-29 | Amedeo Leonardi | Lisinopril/lercanidipine combination therapy |
| US20040110241A1 (en) * | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
| CA2510773C (en) * | 2002-12-16 | 2010-04-13 | Lupin Limited | Crystalline form of quinapril hydrochloride and process for preparing the same |
| CA2510320C (en) | 2002-12-20 | 2012-10-09 | St. James Associates Llc/Faber Research Series | Coated particles for sustained-release pharmaceutical administration |
| CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| CL2004000544A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati |
| CL2004000541A1 (es) * | 2003-03-31 | 2005-02-04 | Warner Lambert Co | Procedimiento de preparacion de clorhidrato de quinapril por reaccion entre una 2,5-dioxo-oxazolidina y un ester terbutilico de una tetrahidro isoquinolina, util como principio activo para tratar la hipertension y la insuficiencia cardiaca congestiva |
| NZ577031A (en) | 2003-05-30 | 2010-09-30 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
| US7459474B2 (en) * | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| US7491743B2 (en) | 2003-08-29 | 2009-02-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
| ES2381551T3 (es) | 2003-12-05 | 2012-05-29 | The Cleveland Clinic Foundation | Marcadores de riesgo para enfermedad cardiovascular |
| US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US20050203168A1 (en) * | 2004-03-11 | 2005-09-15 | The Regents Of The University Of Michigan | Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| EP1809759B1 (en) | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| WO2006083779A2 (en) * | 2005-01-31 | 2006-08-10 | Mylan Laboratories, Inc. | Pharmaceutical composition comprising hydroxylated nebivolol |
| NZ563759A (en) | 2005-05-31 | 2010-06-25 | Mylan Lab Inc | Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate |
| US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
| US20070009591A1 (en) * | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| US8080579B2 (en) * | 2005-10-03 | 2011-12-20 | The Regents Of The University Of Michigan | Compositions and methods for treatment of inflammatory bowel disease |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| WO2007069268A2 (en) * | 2005-10-14 | 2007-06-21 | Sun Pharmaceutical Industries Limited | A process for the preparation of substantially pure 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| WO2007054896A1 (en) | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| CN101432025B (zh) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
| US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007146229A2 (en) * | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
| CN101143846B (zh) * | 2006-09-12 | 2011-02-02 | 南京新港医药有限公司 | 喹那普利拉的金属盐 |
| US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用 |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| BRPI0810409A2 (pt) | 2007-04-18 | 2015-02-18 | Thethys Bioscience Inc | Biomarcadores relacionados ao diabetes e métodos de uso destes |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009042922A2 (en) * | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| WO2009061786A2 (en) * | 2007-11-07 | 2009-05-14 | Janssen Pharmaceutica N.V. | Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists |
| US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| EP2334671A1 (en) | 2008-06-24 | 2011-06-22 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CA2788571A1 (en) | 2010-02-01 | 2011-08-04 | Andrew Redington | Remote ischemic conditioning for treatment and prevention of restenosis |
| EP2552331B1 (en) | 2010-03-31 | 2020-01-08 | The Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
| WO2011127341A2 (en) | 2010-04-08 | 2011-10-13 | The Hospital For Sick Children | Use of remote ischemic conditioning for traumatic injury |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
| MX2014002163A (es) | 2011-08-26 | 2014-09-25 | Wockhardt Ltd | Métodos para el tratamiento de desórdenes cardiovasculares. |
| JP6377054B2 (ja) | 2012-05-11 | 2018-08-22 | リセット セラピューティークス， インコーポレイテッド | クリプトクロム調節薬としてのカルバゾール含有スルホンアミド |
| EP2879666B1 (en) | 2012-08-01 | 2020-04-08 | Tavakoli, Zahra | Free flowing, frozen compositions comprising a therapeutic agent |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| BR112015024234B1 (pt) | 2013-03-21 | 2022-11-16 | Eupraxia Pharmaceuticals USA LLC | Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas |
| BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2014202659A1 (en) | 2013-06-21 | 2014-12-24 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of amides of n-[1-(s)-(ethoxycarbonyl)-3-phenylpropyl]-l-alanine |
| US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| ES2672993T3 (es) | 2015-10-27 | 2018-06-19 | Eupraxia Pharmaceuticals Inc. | Formulaciones de liberación sostenida de anestésicos locales |
| RS66416B1 (sr) | 2019-01-18 | 2025-02-28 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691169A (en) * | 1970-09-03 | 1972-09-12 | Neisler Lab Inc | 2-(alkylthioalkyl)-1,2,3,4-tetrahydroisoquinolines |
| US3929830A (en) * | 1972-08-28 | 1975-12-30 | Velsicol Chemical Corp | N-({60 -thiocyanoacetyl)indolines |
| US4125604A (en) * | 1974-11-08 | 1978-11-14 | Mitsubishi Chemical Industries Limited | N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| US4052511A (en) * | 1976-02-13 | 1977-10-04 | E. R. Squibb & Sons, Inc. | Carboxyacylproline derivatives |
| US4046889A (en) * | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
| US4116962A (en) * | 1976-12-03 | 1978-09-26 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
| US4091024A (en) * | 1976-12-03 | 1978-05-23 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
| US4129566A (en) * | 1978-02-15 | 1978-12-12 | E. R. Squibb & Sons, Inc. | Derivatives of dehydrocyclicimino acids |
| DE2720966C2 (de) | 1977-05-10 | 1991-09-26 | Karl Deutsch Prüf- und Meßgerätebau, 5600 Wuppertal | Ultraschallsender |
| IT7851510A0 (it) | 1977-10-28 | 1978-10-16 | Sandoz Ag | Ammidi di amminoacidi ciclici loro preparazione e loro applicazione quali medicamenti |
| CA1120400A (en) | 1977-12-27 | 1982-03-23 | Zola P. Horovitz | Method of treating hypertension and medicaments therefor |
| US4154935A (en) * | 1978-02-21 | 1979-05-15 | E. R. Squibb & Sons, Inc. | Halogen substituted mercaptoacylamino acids |
| JPS5572169A (en) * | 1978-11-27 | 1980-05-30 | Tanabe Seiyaku Co Ltd | Isoquinoline derivative and its preparation |
| IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4461896A (en) | 1979-02-07 | 1984-07-24 | Norwich Eaton Pharmaceuticals, Inc. | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids |
| DE3063420D1 (en) * | 1979-03-26 | 1983-07-07 | Takeda Chemical Industries Ltd | Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension |
| US4294832A (en) * | 1979-04-28 | 1981-10-13 | Tanabe Seiyaku Co., Ltd. | Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof |
| GB2048863B (en) | 1979-05-16 | 1983-06-15 | Morton Norwich Products Inc | Tetrahydroisoquinoline-3-carboxylic acids |
| US4303583A (en) * | 1979-08-13 | 1981-12-01 | American Home Products Corporation | 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones |
| FR2487829A2 (fr) * | 1979-12-07 | 1982-02-05 | Science Union & Cie | Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| US4251444A (en) * | 1980-04-07 | 1981-02-17 | American Home Products Corporation | Thiazepino-[4,3-b]-isoquinoline-1,5-dione derivatives and precursors |
| EP0278530A3 (de) * | 1980-08-30 | 1989-08-02 | Hoechst Aktiengesellschaft | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung |
-
1981
- 1981-02-20 US US06/236,397 patent/US4344949A/en not_active Expired - Lifetime
- 1981-09-09 IE IE1566/87A patent/IE52666B1/en not_active IP Right Cessation
- 1981-09-09 IE IE2097/81A patent/IE52665B1/en not_active IP Right Cessation
- 1981-09-11 IL IL63806A patent/IL63806A/xx not_active IP Right Cessation
- 1981-09-17 AU AU75416/81A patent/AU551239B2/en not_active Expired
- 1981-09-18 PH PH26222A patent/PH17740A/en unknown
- 1981-09-28 GR GR66144A patent/GR75353B/el unknown
- 1981-09-30 CA CA000387002A patent/CA1341330C/en not_active Expired - Lifetime
- 1981-09-30 FI FI813033A patent/FI78690C/fi not_active IP Right Cessation
- 1981-10-01 JP JP56154900A patent/JPS5788164A/ja active Granted
- 1981-10-01 DE DE8383102092T patent/DE3176029D1/de not_active Expired
- 1981-10-01 EP EP83102092A patent/EP0096157B1/en not_active Expired
- 1981-10-01 DE DE1995175041 patent/DE19575041I2/de active Active
- 1981-10-01 AT AT81304541T patent/ATE25974T1/de active
- 1981-10-01 AT AT83102092T patent/ATE26120T1/de active
- 1981-10-01 DE DE8181304541T patent/DE3176010D1/de not_active Expired
- 1981-10-01 EP EP81304541A patent/EP0049605B1/en not_active Expired
- 1981-10-01 DK DK436081A patent/DK163120C/da not_active IP Right Cessation
- 1981-10-02 KR KR1019810003713A patent/KR880001326B1/ko not_active Expired
- 1981-10-02 MX MX7585A patent/MX155144A/es unknown
- 1981-10-02 DD DD81233850A patent/DD201787A5/de not_active IP Right Cessation
- 1981-10-02 ES ES505960A patent/ES8301925A1/es not_active Expired
- 1981-10-02 NO NO813359A patent/NO159017C/no not_active IP Right Cessation
-
1986
- 1986-02-04 AU AU52991/86A patent/AU563683C/en not_active Expired
-
1987
- 1987-09-16 MY MYPI87001697A patent/MY100440A/en unknown
-
1988
- 1988-04-27 FI FI881985A patent/FI79839C/fi not_active IP Right Cessation
-
1989
- 1989-03-13 SG SG156/89A patent/SG15689G/en unknown
- 1989-05-25 HK HK433/89A patent/HK43389A/en not_active IP Right Cessation
-
1992
- 1992-06-23 CA CA000616411A patent/CA1331614C/en not_active Expired - Lifetime
- 1992-06-23 CA CA000616412A patent/CA1331615C/en not_active Expired - Lifetime
-
1993
- 1993-06-17 NL NL930077C patent/NL930077I2/nl unknown
- 1993-06-22 LU LU88321C patent/LU88321I2/fr unknown
-
1996
- 1996-05-14 NL NL960012C patent/NL960012I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO159017B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater. | |
| US4350704A (en) | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | |
| US4885283A (en) | Phosphinic acid derivatives | |
| US5061722A (en) | Cis, endo-2-azabicyclo-[3.3.0]-octane-3-carboxylic acids, a process for their preparation, agents containing these compounds and their use | |
| FI73698C (fi) | Foerfarande foer framstaellning av nya farmaceutiskt verksamma n-indanylglycinderivat. | |
| EP0037231A2 (en) | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | |
| US5852051A (en) | Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals | |
| US4906615A (en) | Substituted dipeptides as inhibitors of enkephalinases | |
| US4425355A (en) | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids | |
| US4871842A (en) | Piperidine derivatives | |
| CS276179B6 (en) | Process for preparing compounds with nootropic activity | |
| EP0065301A1 (en) | Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same | |
| US4532342A (en) | N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | |
| EP0058567B1 (en) | Substituted acyl derivatives of octahydro-1h-isoindole-1-carboxylic acids and esters | |
| US4503043A (en) | Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids | |
| SU1148560A3 (ru) | Способ получени замещенного ацилового производного 1,2,3,4-тетрагидроизохинолин-3-карбоновой кислоты или его фармацевтически приемлемых солей | |
| CA1313724C (en) | Aminoacid derivatives as antihypertensives | |
| EP0059966A1 (en) | Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives | |
| KR880001007B1 (ko) | 비사이클릭 화합물의 제조 방법 | |
| JPH01110695A (ja) | アミノ酸誘導体その製造方法及び血圧降下剤 | |
| HU187880B (en) | Process for preparing octqhydro-1h-indola-2-carboxylic acid acyl derivatives | |
| IE52664B1 (en) | Substituted acyl derivative of octahydro-1h-indole-2-carboxylic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |
Free format text: EXPIRED IN OCTOBER 2001 |